CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease

Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, 81675 München, Germany.
Neurology (Impact Factor: 8.29). 06/2011; 77(1):35-8. DOI: 10.1212/WNL.0b013e318221ad47
Source: PubMed


To explore if soluble amyloid precursor proteins (sAPP) in CSF improve the identification of patients with incipient Alzheimer disease (AD) in a group of patients with mild cognitive impairment (MCI).
A cohort study with follow-up assessments of 58 patients with MCI with baseline CSF sampling was conducted: 21 patients had progressed to probable AD (MCI-AD), 27 still had MCI, 8 had reverted to normal (MCI-NAD), and 2 patients with frontotemporal dementia (FTD) were excluded. Sixteen additional patients with FTD were included to explore the specificity of the CSF markers. CSF concentrations of sAPPα, sAPPβ, tau, and Aβ(1-42) were measured with sensitive and specific ELISAs. Associations between diagnostic status, CSF protein concentrations, and other patient characteristics were explored using multiple logistic regression analyses with stepwise variable selection. The optimal sensitivity and specificity of the best models were derived from receiver operating characteristic curves.
The MCI-AD group had significantly higher sAPPβ concentrations than the MCI-NAD and the FTD groups. A combination of sAPPβ, tau, and age differentiated the MCI-AD and the MCI-NAD groups with a sensitivity of 80.00% and a specificity of 81.00%. The best model for the differentiation of the MCI-AD and the FTD groups included sAPPβ and tau, and showed a sensitivity of 95.20% and a specificity of 81.20%. Aβ(1-42) and sAPPα did not significantly contribute to the models.
These findings suggest that sAPPβ may be clinically useful, and superior to Aβ(1-42), in the early and differential diagnosis of incipient AD.

Download full-text


Available from: Panagiotis Alexopoulos, Feb 25, 2014
  • Source
    • "Thus, Biomarkers are needed to facilitate early identification of aMCI and predict progression to dementia. The methods used to search for biomarkers of aMCI include scales (Duchesne et al., 2005; Hoops et al., 2009; Kasten et al., 2010), neuroimaging techniques (Small et al., 2006; Hamalainen et al., 2007), cerebrospinal fluid analysis (Perneczky et al., 2011), and genetic analysis (Zhang et al., 2012), which are invasive or expensive or requires a high level of education, could not be widely used in rural population. Hence, the identification of objective biomarkers that are sensitive to the pathophysiological changes in aMCI and easily accepted in rural population is important for both prevention of dementia and promotion of health. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim was to evaluate the Mismatch Negativity (MMN) component, a correlate of the automatic detection of changes in the acoustic environment, in healthy adults and adults with aMCI. 43 mild amnestic cognitive impairment (aMCI) subjects and 43 healthy Chinese older adults were arranged into experimental group and control group respectively. Their MMN amplitude and latency were measured at the FZ, FCZ and CZ electrode sites under a passive auditory oddball task. The results showed that the latencies obtained from the FZ, FCZ and CZ electrode sites were significantly longer in the aMCI adults than in the control adults (P
    Full-text · Article · Mar 2015 · Frontiers in Aging Neuroscience
  • Source
    • "Thus it is of great importance to diagnose AD at an early stage and perform effective interventions before cognitive symptoms emerge. Although some cerebrospinal fluid (CSF) biomarkers and amyloid imaging have been established to detect AD pre-clinically [5], [6], these are not suitable for large scale screening programs in consideration of the invasiveness and a host of comorbidities. Taking into account these facts, finding proteins from peripheral blood samples that could identify AD may be useful for pre-symptomatic. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral blood Apolipoprotein E (ApoE) levels have been proposed as biomarkers of Alzheimer's disease (AD), but previous studies on levels of ApoE in blood remain inconsistent. This meta-analysis was designed to re-examine the potential role of peripheral ApoE in AD diagnosis and its potential value as a candidate biomarker. We conducted a systematic literature search of MEDLINE, EMBASE, the Cochrane library, and BIOSIS previews for case-control studies measuring ApoE levels in serum or plasma from AD subjects and healthy controls. The pooled weighted mean difference (WMD) and 95% confidence interval (CI) were used to estimate the association between ApoE levels and AD risk. Eight studies with a total of 2250 controls and 1498 AD cases were identified and analyzed. The pooled WMD from a random-effect model of AD participants compared with the healthy controls was -5.59 mg/l (95% CI: [-8.12, -3.06]). The overall pattern in WMD was not varied by characteristics of study, including age, country, assay method, publication year, and sample type. Our meta-analysis supports a lowered level of blood ApoE in AD patients, and indicates its potential value as an important risk factor for AD. Further investigation employing standardized assay for ApoE measurement are still warranted to uncover the precise role of ApoE in the pathophysiology of AD.
    Full-text · Article · Feb 2014 · PLoS ONE
  • Source
    • "The establishment of aMCI biomarkers would be of benefit to clinicians as the biomarkers could be used as objective diagnostic tools, thus allowing early or pre-symptomatic identification of AD, aiding treatment decisions, monitoring disease progress, and providing opportunities for prevention by population screening (Henry et al., 2012). The methods used to search for biomarkers of MCI include neuroimaging techniques (Small et al., 2006; Hämäläinen et al., 2007), cerebrospinal fluid analysis (Perneczky et al., 2011), genetic analysis (Zhang et al., 2012) and electroencephalography (EEG), both quantitative EEG (see Jackson and Snyder, 2008) and event-related potentials (ERPs; see Jackson and Snyder, 2008 and Vecchio and Määttä, 2011). The use of ERP technique in the search for aMCI biomarkers is founded on three essential characteristics designated as ideal (see Hampel et al., 2010): it is non-invasive, simple to measure and inexpensive. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It has been suggested that changes in some event-related potential (ERP) parameters associated with controlled processing of stimuli could be used as biomarkers of amnestic mild cognitive impairment (aMCI). However, data regarding the suitability of ERP components associated with automatic and involuntary processing of stimuli for this purpose are not conclusive. In the present study, we studied the Mismatch Negativity (MMN) component, a correlate of the automatic detection of changes in the acoustic environment, in healthy adults and adults with aMCI (age range: 50-87 years). An auditory-visual attention-distraction task, in two evaluations separated by an interval of between 18 and 24 months, was used. In both evaluations, the MMN amplitude was significantly smaller in the aMCI adults than in the control adults. In the first evaluation, such differences were observed for the subgroup of adults between 50 and 64 years of age, but not for the subgroup of 65 years and over. In the aMCI adults, the MMN amplitude was significantly smaller in the second evaluation than in the first evaluation, but no significant changes were observed in the control adult group. The MMN amplitude was found to be a sensitive and specific biomarker of aMCI, in both the first and second evaluation.
    Full-text · Article · Dec 2013 · Frontiers in Aging Neuroscience
Show more